ABSTRACT
An 80-year-old man with history of prostate cancer successfully treated with brachytherapy was initially thought to have Fournier's gangrene until imaging detected a rectoprostatic fistula. Although this is known to be a rare complication of prostate brachytherapy, in this case the aetiology was a new primary rectal adenocarcinoma. It was not possible to catheterise per urethra owing to the fistula, so he was fitted with suprapubic catheter, and underwent palliative loop colostomy. Brachytherapy carries a low risk of second primary cancers, although two previous cases reported such cancers as radiation induced. This is, to our knowledge, the first case of rectal adenocarcinoma following prostate brachytherapy in the literature.
Subject(s)
Adenocarcinoma/pathology , Brachytherapy/adverse effects , Neoplasms, Radiation-Induced/pathology , Prostate/pathology , Prostatic Neoplasms/radiotherapy , Rectal Fistula/pathology , Rectal Neoplasms/pathology , Rectum/pathology , Adenocarcinoma/chemically induced , Adenocarcinoma/diagnostic imaging , Aged, 80 and over , Humans , Male , Neoplasms, Radiation-Induced/diagnostic imaging , Palliative Care , Prostate/diagnostic imaging , Prostate/radiation effects , Rectal Fistula/chemically induced , Rectal Fistula/diagnostic imaging , Rectal Neoplasms/chemically induced , Rectal Neoplasms/diagnostic imaging , Rectum/radiation effects , Treatment OutcomeSubject(s)
Abscess/chemically induced , Adalimumab/adverse effects , Antirheumatic Agents/adverse effects , Cutaneous Fistula/chemically induced , Drug Eruptions/etiology , Rectal Fistula/chemically induced , Spondylitis, Ankylosing/drug therapy , Female , Hidradenitis Suppurativa/chemically induced , Humans , Psoriasis/chemically induced , Young AdultSubject(s)
Fournier Gangrene/chemically induced , Perineum , Scrotum , Steroids/adverse effects , Thrombocytopenia/drug therapy , Aged , Anti-Bacterial Agents/therapeutic use , Debridement/methods , Fournier Gangrene/diagnostic imaging , Humans , Male , Radiography , Rectal Fistula/chemically induced , Rectal Fistula/diagnostic imagingABSTRACT
AIMS OF STUDY: Retinoid-mediated signal transduction plays a crucial role in the embryogenesis of various organs. We previously reported the successful induction of anorectal malformations in mice using retinoic acid (RA). Retinoic acid controls the expression of essential target genes for cell differentiation, morphogenesis, and apoptosis through a complicated interaction in which RA receptors form heterodimers with retinoid X receptors. In the present study, we investigated whether the retinoid antagonist, LE135, could prevent the induction of anorectal malformations (ARMs) in mice. METHODS: Retinoic acid was intraperitoneally administered as 100 mg/kg of all-trans RA on E9; and then the retinoid antagonist, LE135, was intraperitoneally administered to pregnant ICR strain mice on the eighth gestational day (E8), 1 day before administration of RA (group B) or on E9, simultaneously (group C) with RA administration. All of the embryos were obtained from the uteri on E18. Frozen sections were evaluated for concentric layers around the endodermal epithelium by hematoxylin and eosin staining. RESULTS: In group A, all of the embryos demonstrated ARM with rectoprostatic urethral fistula, or rectocloacal fistula, and all of the embryos showed the absence of a tail. In group B, 36% of the embryos could be rescued from ARM. However, all of the rescued embryos had a short tail that was shorter than their hind limb. The ARM rescue rates in group B were significantly improved compared to those in group A (P < .01). In group C, 45% of the embryos were rescued from ARM, but all of the rescued embryos had short tail. The ARM rescue rate in group C was significantly improved compared to that in group A (P < .01). However, there was no significant difference in the ARM rescue rate between group B and Group C. CONCLUSION: The present study provides evidence that in the hindgut region, RAR selective retinoid antagonist, LE135, could rescue embryos from ARM. However, the disturbance of all-trans RA acid was limited to the caudal region. Further study to establish an appropriate rescue program for ARM in a mouse model might suggest a step toward protection against human ARM in the future.
Subject(s)
Abnormalities, Drug-Induced/prevention & control , Abnormalities, Multiple/prevention & control , Anal Canal/abnormalities , Dibenzazepines/therapeutic use , Receptors, Retinoic Acid/antagonists & inhibitors , Rectum/abnormalities , Tretinoin/toxicity , Abnormalities, Drug-Induced/embryology , Abnormalities, Drug-Induced/etiology , Abnormalities, Multiple/chemically induced , Abnormalities, Multiple/embryology , Animals , Cloaca/abnormalities , Cloaca/embryology , Dibenzazepines/administration & dosage , Dibenzazepines/pharmacology , Drug Administration Schedule , Drug Evaluation, Preclinical , Female , Fistula/chemically induced , Fistula/embryology , Fistula/prevention & control , Gene Expression Regulation, Developmental/drug effects , Humans , Injections, Intraperitoneal , Male , Mice , Mice, Inbred ICR , Models, Animal , Pregnancy , Prostatic Diseases/chemically induced , Prostatic Diseases/embryology , Prostatic Diseases/prevention & control , Random Allocation , Rectal Fistula/chemically induced , Rectal Fistula/embryology , Rectal Fistula/prevention & control , Species Specificity , Tail/abnormalities , Tretinoin/administration & dosageSubject(s)
Adjuvants, Immunologic/adverse effects , BCG Vaccine/adverse effects , Carcinoma in Situ/drug therapy , Fistula/chemically induced , Prostatic Diseases/chemically induced , Rectal Fistula/chemically induced , Urinary Bladder Neoplasms/drug therapy , Adjuvants, Immunologic/administration & dosage , Administration, Intravesical , Aged , BCG Vaccine/administration & dosage , Humans , MaleSubject(s)
Angiogenesis Inhibitors/adverse effects , Antibodies, Monoclonal/adverse effects , Antineoplastic Agents/adverse effects , Benzenesulfonates/adverse effects , Pyridines/adverse effects , Rectal Fistula/chemically induced , Antibodies, Monoclonal, Humanized , Bevacizumab , Female , Humans , Middle Aged , Niacinamide/analogs & derivatives , Phenylurea Compounds , SorafenibSubject(s)
Antibodies, Monoclonal/adverse effects , Rectal Fistula/chemically induced , Rectal Neoplasms/drug therapy , Aged , Antibodies, Monoclonal/therapeutic use , Antibodies, Monoclonal, Humanized , Bevacizumab , Female , Humans , Male , Middle Aged , Rectal Fistula/diagnostic imaging , Tomography, X-Ray ComputedSubject(s)
Ergotamine/adverse effects , Fecal Incontinence/etiology , Migraine Disorders/drug therapy , Rectal Fistula/chemically induced , Vaginal Fistula/chemically induced , Adult , Analgesics, Non-Narcotic/adverse effects , Ergotism/complications , Female , Humans , Intestinal Obstruction/chemically induced , Rectal Diseases/chemically induced , SuppositoriesABSTRACT
Radiological imaging of the pelvis adds an important dimension to our understanding of rectal and perianal disease. By integrating relevant information obtained from these investigations into planning and conduct of surgical procedures, outcomes for patients may be optimised. This review focuses on three areas from a clinical viewpoint. (1) With the increased use of neoadjuvant treatments pretherapeutic staging strategies become central to the management of rectal cancer patients. At present, transrectal ultrasound (TRUS), computerised tomography and magnetic resonance imaging (MRI) serve in combination to provide the essential informations. (2) The advent of endoanal ultrasound and MRI in the diagnostic workup of patients with faecal incontinence has caused a paradigm shift both conceptionally and in the way treatments are tailored to individual patients. (3) Concerning primary perianal fistulas there is little place for endoanal ultrasound or MRI. However, when a recurrent or Crohn's fistula is present, a combination of surgical exploration with either endoanal ultrasound or MRI depending on local expertise and availability may be the optimal approach to maximise benefit for these patients.
Subject(s)
Diagnostic Imaging , Fecal Incontinence/diagnosis , Rectal Fistula/chemically induced , Rectal Neoplasms/diagnosis , Endosonography , Humans , Magnetic Resonance Imaging , Pelvic Floor/pathology , Preoperative Care , Tomography, X-Ray ComputedABSTRACT
Since high anorectal malformations with fistulae in human embryos and fetuses of successive developmental stages have not been reported, the embryologic relationship between the rectal fistula (RF) and the genitourinary tract (GUT) in high anorectal agenesis (ARA) remains to be elucidated. This study investigates the developmental relationship between the RF and the GUT in male and female fetuses with high ARA using our established model for high ARA with fistula in mice. Pregnant mice received all-trans retinoic acid suspended in corn oil (5 mg/ml) 100 mg/kg i.p. on day 9 of pregnancy. All fetuses were removed from the uterus on a single day from days 12 to 18 of pregnancy. The caudal regions were analyzed histologically with hematoxylin and eosin staining. All fetuses examined had high ARA with fistula. On day 12 of pregnancy, an anomalous communication was seen between the urogenital sinus (UGS) and the rectum. In the affected female fetuses, on day 14 of pregnancy the paramesonephric (müllerian) ducts and müllerian tubercle were located above the rectocloacal fistula (RCF), and on day 18 of pregnancy the uterovaginal canal was located between the cloaca and the RCF. In the male fetuses, on day 14 of pregnancy the junction between the mesonephric (wolffian) duct and the UGS was located away from the junction between the rectum and the UGS. On day 18 of pregnancy the ejaculatory duct was located between the urinary bladder and the rectourethral fistula. The results of our experiment clearly show the embryologic relationship between the RF and the GUT with high ARA. The anomalous communication between the UGS and the rectum may interfere with normal caudal migration along the dorsal wall of the UGS at the junction between the UGS and the mesonephric or paramesonephric duct.
Subject(s)
Anal Canal/abnormalities , Digestive System Abnormalities/chemically induced , Rectal Fistula/chemically induced , Rectum/abnormalities , Tretinoin , Urogenital Abnormalities/chemically induced , Anal Canal/embryology , Animals , Disease Models, Animal , Female , Fetus/drug effects , Male , Mice , Pregnancy , Rectum/embryology , Tretinoin/toxicityABSTRACT
We report on the experimental induction of anorectal malformations (ARM) and other internal and external malformations in mouse fetuses induced by maternal administration of etretinate, a long-acting vitamin A analogue. The teratogen was administered to pregnant mice between the 7th and 10th gestational days (E7 and E10). The mice of the control group were given pure sesame oil on E9. We examined survival rates, crown-rump length, and the incidence of internal and external malformations, with particular attention to ARM, in each group. All mice in the E8 group exhibited rectovesical fistula, hydronephrosis, and spina bifida. All males and females in the E9 group given 60 mg/kg of etretinate developed rectoprostatic urethral fistula and rectocloacal fistula, respectively. The E10 group, given 60 mg/kg of etretinate displayed cleft palate (63.6%), forelimb malformation (68.2%), and a short club-shaped tail (100%). The fetuses had more severe types of ARM when etretinate had been administered on an earlier gestational day. The E9 group is a useful model for anorectal malformation, whereas the E8 group is a model for hydronephrosis and spina bifida.